普拉克索联合高压氧舱治疗帕金森病合并睡眠障碍的效果

Abstract
Figure/Table
References (23)
Related Citation (9)

Download: PDF (825 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To discuss the curative effect of Pramipexole and hyperbaric oxygen chamber in the treatment of Parkinson disease combined with dyssomnia. Methods The clinical data of 135 patients with Parkinson disease combined with dyssomnia treated in Affiliated Hospital of Yan'an University from December 2014 to December 2016 was analyzed retrospectively. The patients were divided into three groups according to different treatment methods, with 45 cases in each group. The patients in the Pramipexole group were treated with oral Pramipexole Dihydrochloride Tablets, and the patients in the hyperbaric oxygen chamber group were treated with hyperbaric oxygen therapy, the patients in the combination group were treated with hyperbaric oxygen and Pramipexole Dihydrochloride Tablets. All groups were treated for 2 months. The sleep related indices (time in bed, total sleep time, sleep efficiency, sleep onset latency, number of awakenings) and polysomnogram monitoring parameters [sleep time at phase Ⅰ-Ⅱ, slow-wave sleep (SWS), and rapid eye movement sleep (REM) time] after treatment in the three groups were observed and recorded. The scores of Pittsburgh sleep quality index scale (PSQI), Epworth sleepiness scale (ESS), unified Parkinson disease rating scale (UPDRS-Ⅲ), Hoehn-Yahr grading (H-Y grading) of Parkinson disease among the three groups before and after treatment were compared. The conditions of adverse reactions in the three groups were recorded. Results There were no significant differences in the scores of sleep quality related scales among the three groups before treatment (P ＞ 0.05). There were no statistically significant differences in the scores of sleep quality related scales of the Pramipexole group and hyperbaric oxygen chamber group before and after treatment (P ＞ 0.05), while the scores of PSQI, ESS and UPDRS-Ⅲ after treatment in the combination group were significantly lower than those before treatment (P ＜ 0.05), and the scores of PSQI and ESS in the combination group were significantly lower than those of Pramipexole group and hyperbaric oxygen chamber group (P ＜ 0.05), while the scores of UPDRS-Ⅲ and H-Y grading had no significant differences compared with those of Pramipexole group and hyperbaric oxygen chamber group (P ＞ 0.05). After treatment, the time in bed, total sleep time and sleep efficiency in the combination group were significantly higher than those of Pramipexole group and hyperbaric oxygen chamber group (P ＜ 0.05), the number of awakenings was significantly less than those of Pramipexole group and hyperbaric oxygen chamber group (P ＜ 0.05). There were no statistically significant differences of the other sleep indices among the three groups (P ＞ 0.05). No obvious adverse reactions occurred in the three groups after treatment. Conclusion Pramipexole combined with hyperbaric oxygen chamber in the treatment of Parkinson disease combined with dyssomnia has significant clinical effect, which can significantly improve sleep efficiency and quality, it is worthy of clinical promotion.

Key words： Parkinson disease Dyssomnia Pramipexole Hyperbaric oxygen chamber

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yingying GAO Xibin MA Li SHI Qiang▲

Cite this article:

LIU Yingying GAO Xibin MA Li SHI Qiang▲. Curative effect of Pramipexole combined with hyperbaric oxygen chamber in the treatment of Parkinson disease combined with dyssomnia[J]. 中国医药导报, 2018, 15(11): 78-81,90.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I11/78

[1] 潘燕，罗梅，王新源，等.普拉克索联合高压氧舱治疗帕金森病合并睡眠障碍的疗效观察[J].中华老年心脑血管病杂志，2016，18（2）：125-128.
[2] 王广杰.普拉克索联合高压氧舱治疗帕金森病伴睡眠障碍患者的疗效观察[J].国际医药卫生导报，2017，23（2）：186-189.
[3] 刘玉祥.普拉克索联合高压氧舱治疗帕金森病合并睡眠障碍患者的临床效果[J].中国医药导报，2016，13（16）：50-53.
[4] 郭仙忠，吴钢，王长连，等.多巴丝肼片合用多巴胺受体激动剂治疗帕金森病临床疗效观察[J].中华神经医学杂志，2012，11（3）：286-289.
[5] 王月英.普拉克索联合左旋多巴治疗帕金森病的临床观察[J].中国医药导刊，2014，16（1）：88-89，91.
[6] 姜立刚，李海平，李威，等.美多巴单用及联合普拉克索治疗帕金森病的疗效和安全性比较[J].中国老年学杂志，2016，36（2）：424-425.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会.中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49（4）：268-271.
[8] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第三版）[J].中华神经科杂志，2014， 43（6）：428-433.
[9] Leentjens AF，Moonen AJ，Dujardin K，et al. Modeling depression in Parkinson disease Disease -specific and nonspecific risk factors [J]. Neurology，2013，81（12）：1036-1043.
[10] Postuma RB，Aarsland D，Barone P，et al. Identifying prodromal Parkinson's disease：pre-motor disorders in Parkinson's disease [J]. Mov Disord，2012，27（5）：617-626.
[11] 龙武，杨期明，蒋柏菊，等.普拉克索治疗帕金森病运动并发症的临床疗效观察[J].国际神经病学神经外科学杂志，2013，40（2）：118-122.
[12] 黄婷婷，张勇，卢祖能.帕金森病睡眠障碍的病理生理学机制、分类和治疗[J].中国老年学杂志，2016，36（23）：6028-6031.
[13] 欧阳樱君，邱恒峰，赖明君，等.普拉克索治疗帕金森病合并抑郁的效果及患者磁共振波谱的改变[J].广东医学，2014，35（15）：2420-2421.
[14] 张克忠，袁永胜，宋春杰，等.盐酸普拉克索改善帕金森病非运动症状疗效观察[J].中国实用神经疾病杂志，2012， 15（14）：11-14.
[15] 吴桂英，师聪红.普拉克索治疗帕金森病的疗效分析[J].中国医药导报，2011，8（7）：73-74.
[16] 韩睿，陈荣.帕金森病睡眠障碍发病机制及其治疗的研究进展[J].药学进展，2015，39（8）：592-597.
[17] Keisuke S，Yasuyuki O，Tomoyuki U，et al. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson′s disease：a multicentre cross-sectional study [J]. J Neurol Neurosurg Psychiatry，2017， 88（11）：953-959.
[18] Schrempf W，Brandt MD，Storch A，et al. Sleep disorders in Parkinson's disease [J]. J Parkinsons Dis，2014，4（2）：211-221.
[19] 祁钰.中西药物联用治疗帕金森病52例[J].西部中医药，2016，29（8）：108-110.
[20] 余丹丽，张雄.普拉克索在帕金森病中的应用[J].实用医学杂志，2009，25（1）：20-21.
[21] 李蓉，李晋芳.帕金森病相关睡眠障碍的药物治疗[J].国际神经病学神经外科学杂志，2016，43（2）：175-178.
[22] 冉宁晶，杨芳，陈卫银，等.郁乐疏合剂治疗帕金森病伴发抑郁的临床疗效[J].西部中医药，2017，30（7）：89-93.
[23] 胡火有，韩漫夫，肖小华，等.添加普拉克索治疗对帕金森病患者评分及非运动症状的影响分析[J].中风与神经疾病杂志，2016，33（5）：425-428.